Search

Displaying results 5841 - 5850 of 6189 in total
  1. Drug

    DLO6001

    go.drugbank.com/drugs/DB05178
    Experimental

    DL6001 is developed by DanioLabs using proprietary zebrafish technology to treat Parkinson’s disease symptoms including sialorrhoea and hyperhidrosis.

  2. Drug

    TA-NIC

    go.drugbank.com/drugs/DB05445
    Investigational

    TA-NIC is a novel and proprietary vaccine in development as an aid to quitting smoking in motivated patients. It is designed to raise anti-nicotine antibodies which bind to nicotine molecules in the patient's blood stream, reducing the r...

  3. Drug

    Cantuzumab ravtansine

    go.drugbank.com/drugs/DB05594
    Investigational

  4. Drug

    OTI-030

    go.drugbank.com/drugs/DB05648
    Investigational

  5. Drug

    Iodofiltic acid I-123

    go.drugbank.com/drugs/DB05683
    Investigational

  6. Drug

    R-1487

    go.drugbank.com/drugs/DB06518
    Experimental

  7. Drug

    Aldoxorubicin

    go.drugbank.com/drugs/DB06013
    Investigational

    Aldoxorubicin, an antineoplastic agents, is an albumin-binding prodrug of doxorubicin.

  8. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is the first in a series of proprieta...

  9. Drug

    rhIGFBP-3

    go.drugbank.com/drugs/DB05897
    Investigational

    rhIGFBP-3 (recombinant human insulin-like growth factor binding protein-3) is Insmed’s proprietary anti-cancer compound that has demonstrated significant decreases in cancerous growth in several models of human. It is developed by Insmed...

  10. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival. AZD-8330 has shown tumor suppressive activity in multiple preclinical models of h...